Plasma Neuregulin 4 Levels Are Associated with Metabolic Syndrome in Patients Newly Diagnosed with Type 2 Diabetes Mellitus

Table 4

Odds ratios for the presence of MetS according to plasma Nrg4 concentration in all nT2DM patients.

	Increased MetS OR (95% CI)	P value
Model 1	0.85 (0.752–0.961)	0.009
Model 2	0.833 (0.717–0.967)	0.016
Model 3	0.750 (0.574–0.980)	0.035
Model 4	0.741 (0.555–0.990)	0.042
Model 5	0.683 (0.492–0.947)	0.022
Model 6	0.560 (0.374–0.837)	0.005

OR: odds ratio; CI: confidence interval. Model 1 unadjusted; model 2 adjusted for sex, age, and parameters of adiposity (BMI and BF%); model 3 adjusted for factors listed in model 2 plus parameters of glycolipid metabolism (SBP, DBP, FPG, 2hPG, HbA1c, TC, TG, HDL-C, LDL-C, apoA, and apoB); model 4 adjusted for factors listed in model 3 plus measures of insulin resistance (apoB/apoA, TyG index, FIns, HOMA-IR, and HOMA-IS); model 5 adjusted for factors listed in model 4 plus markers of inflammation (WBC count, neutrophil count, lymphocyte count, NLR, and hs-CRP); model 6 adjusted for factors listed in model 4 plus biomarkers of liver function (ALT, AST, GGT, and ALP).